{"ticker": {"uuid": "48718c7b-5ac6-435c-b248-efa0c6cb8a13", "symbol": "CUE", "name": "Cue Biopharma", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Form 4 Cue Biopharma For: 15 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPVHlMRmEwdXc3bWVGR1AtMFYzT3AyT2E0TzB1Ml9Ld254TUxFaDdxMWJwanB0WWc5V2FMUm5SNi01WG1pRnotVUs1djRZTDh6RV9hZTlwX0pDSWdvMDRkNnZCZDZkWTlGLWZRT19WQlN0YXphdW14aFhuaGF2djd3Vjg2UVlPb0xSTXpXLWRCYUdIMmpISWRiMA?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-15T23:05:10+00:00", "published_display": "15 Jul 2026 23:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma (CUE) awards RSUs and stock options to CMO Borie", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQcEFTNWNjWURQY1Izck5uWVFmaVBjSWltWnR1b1J3eFdnNW1fLTJXbXR4cHhWYjl4bXoxbmhkenJwMXBXaGZNbHhSb1VlaVM4YXBxNWlmYkZ1WlJid2huTnpaMkRPeGNVR29GWExGZ3JfcVBOaE9RckNnQkVfWGFxWGlVajlNYWtmMm9tSENUMVFhTzA2NERHS002LW5VNjdKYXlBbkdlMzN5ckxtT1d3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T23:00:15+00:00", "published_display": "15 Jul 2026 23:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma (NASDAQ: CUE) CMO Dominique Borie files initial Form 3", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQbEJ5aUN6Nm16cWxEQnRCSnFVQThTMVRJVjEtX2RCOTlKSHVFdVZkbGRHbktHX29GeG16bC00d0tfR0N4SXQ3U0ctaURjUThZRlJMM2ZJQm5ZME8zSV9ZRHBIZXBsT1ZTSGhnVGJnZ2llU2JZdEliWEpicXdCUEx0VXhSTWMxeEhsNFZOcmtpNno0YWVrRGo5SGlIYWhsLU84T3F1Wk9hSVlJM0E2WW9MSXlERGhiekJsVGN2V1NyR0d4cE9taFE?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T22:58:49+00:00", "published_display": "15 Jul 2026 22:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development", "summary": "Cue Biopharma (Nasdaq: CUE) has appointed Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development. Dr. Borie brings over two decades of experience in immunology and clinical development to the company and will report to President and CEO Shao-Lee L", "url": "https://www.globenewswire.com/news-release/2026/07/13/3326185/0/en/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development.html", "source_name": "GlobeNewswire", "published_at": "2026-07-13T15:40:13", "published_display": "13 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cue Biopharma names Dominic Borie as chief medical officer", "summary": "Cue Biopharma has appointed Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development. This strategic move coincides with the company's advancement of therapies for immune-mediated diseases, including upcoming Phase 2 data for CUE-221 and the initiat", "url": "https://www.investing.com/news/company-news/cue-biopharma-names-dominic-borie-as-chief-medical-officer-93CH-4788521", "source_name": "Investing.com", "published_at": "2026-07-13T13:09:56", "published_display": "13 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Cue Biopharma, Inc. Stocks", "summary": "This article lists Exchange Traded Funds (ETFs) that hold stocks of Cue Biopharma, Inc. (CUE). It highlights one such fund, the iShares Microcap ETF (IWC), providing details like its market value, weight of CUE stock, expense ratio, and performance. The information aims to help i", "url": "https://www.tradingview.com/symbols/NASDAQ-CUE/etfs/?exchange=NASDAQ", "source_name": "TradingView", "published_at": "2026-07-13T13:09:55", "published_display": "13 Jul 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunology veteran Dominic Borie to steer Cue Biopharma\u2019s drug pipeline", "summary": "Cue Biopharma (Nasdaq: CUE) has appointed Dominic Borie, M.D., Ph.D., as its Chief Medical Officer and Head of Research & Development. This strategic hire aligns with the company's advancement of its clinical programs, including an expected Phase 2 CSU data readout for CUE-221 by", "url": "https://www.stocktitan.net/news/CUE/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-0b47z37jap4b.html", "source_name": "Stock Titan", "published_at": "2026-07-13T12:09:55", "published_display": "13 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Stocks At 52-Week Highs: AMWL, CUE, ICCC, SRRK, FTH", "summary": "Several biotech stocks, including American Well Corporation (AMWL), Cue Biopharma Inc. (CUE), ImmuCell Corporation (ICCC), Scholar Rock Holding Corp. (SRRK), and Faeth Therapeutics Inc. (FTH), reached 52-week highs on July 10, 2026. These highs were driven by positive development", "url": "https://www.rttnews.com/amp/3666350/biotech-stocks-at-52-week-highs-amwl-cue-iccc-srrk-fth.aspx", "source_name": "RTTNews", "published_at": "2026-07-13T11:09:56", "published_display": "13 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Cue Biopharma, Inc. \u2013 MUN:1UC0", "summary": "This article provides access to financial data for Cue Biopharma, Inc. (1UC0) on the Munich Stock Exchange, specifically focusing on its forward price-to-earnings ratio. It seems to be a financial data page from TradingView, offering an overview of the company's financial perform", "url": "https://www.tradingview.com/symbols/MUN-1UC0/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T19:40:43", "published_display": "12 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Cue Biopharma, Inc. \u2013 MUN:1UC0", "summary": "This article displays the \"Enterprise value to revenue forward\" metric for Cue Biopharma, Inc. (MUN:1UC0) on the Munich Stock Exchange, as provided by TradingView. It shows that the market is currently closed with no trades recorded for this particular metric. The content highlig", "url": "https://www.tradingview.com/symbols/MUN-1UC0/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T08:39:50", "published_display": "12 Jul 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma (CUE) director receives 21,800-share restricted stock unit grant", "summary": "Meehan Viola Mong, a director at Cue Biopharma, received a grant of 21,800 restricted stock units (RSUs) of Common Stock. These RSUs were granted at $0.00 per share and will vest in three equal installments on July 9, 2027, July 9, 2028, and July 9, 2029, contingent on continued ", "url": "https://www.stocktitan.net/sec-filings/CUE/form-4-cue-biopharma-inc-insider-trading-activity-32dc7de8f257.html", "source_name": "Stock Titan", "published_at": "2026-07-11T15:40:13", "published_display": "11 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma (Nasdaq: CUE) secures $50M private placement and grants over 1M RSUs", "summary": "Cue Biopharma (Nasdaq: CUE) has successfully completed a private placement, raising approximately $50.0 million from accredited investors including Cormorant Asset Management and Columbia Threadneedle Investments. This financing involved issuing common stock and pre-funded warran", "url": "https://www.stocktitan.net/sec-filings/CUE/8-k-cue-biopharma-inc-reports-material-event-a63e850859e8.html", "source_name": "Stock Titan", "published_at": "2026-07-11T02:11:12", "published_display": "11 Jul 2026 02:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma (CUE) awards 21,800 time-vested RSUs to director Garzone", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNSDgwb2JtMG83V2hkVDRGOS0zNjNTTjVaVVlIVXJJWEFHOHhlVWVfRFp3Uk9GN2FsekZjSDRnaXptam8waHJTX0hzbVcwOVF1Q2FsYW9LN0lNQ2owcmVETlYwX0FHT2ZOVS1uaDFvR0NrSkREVzFHMEFKUG1iWFVwTlJCYkV0bGVMLWd5dFdQajQxNEVfbUlGUHpNVlNEeDBReFBqVmoxMlNPWS1GZktj?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T23:38:30+00:00", "published_display": "10 Jul 2026 23:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Cue Biopharma For: 10 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQRWZ5c25LTDZ5NFlvUXlBRGR1cGhMV0phQ0YzNTNKbC1meU5IMFZBbnV6aDQtMXp1dU5rUmxKSWwxczZMTFhRUXl3cHA0YmxUSGFvRnJaVFlqZndmQm4zMXJ2d2VyellSbTdmOHZWekpoYWxaZ3dIMWx5bTllX0IxakdKbEtxRm54M1lJcmYwXzlycnoyUzRBcg?oc=5", "source_name": "Investing.com UK", "published_at": "2026-07-10T23:38:00+00:00", "published_display": "10 Jul 2026 23:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma (CUE) awards 40,942 RSUs and 40,942 PSUs to accounting chief", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOd3ZrSkJqM1BEZDB6NDFmYW9iOXV4YlBuVDdBZlZmNVdoWUN6bWNWUTBGRkJGdS10UkhEVEpuMFFYTDRKdjk5cVVOZTB4bWRrdGJMcDk2NHh0TWppMFR6UUFkanJzTkxnRVlBc2VNTGcxUlhsM2ZjOEpLZmtmZmdhcl8xQzMwNmJfcHl3N1VEbUFJOGV0RVlWNWFwUjM4cTBqNm9kMHdJSHFkWGUwUWlN?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T23:34:53+00:00", "published_display": "10 Jul 2026 23:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma (CUE) awards 109,178-share RSU and PSU package to legal chief", "summary": "Cue Biopharma, Inc. granted its Chief Legal Compliance Officer and Corporate Secretary, Sumita Ray, a total of 109,178 shares in equity awards. This package includes 54,589 restricted stock units (RSUs) vesting quarterly over 48 months and 54,589 performance stock units (PSUs) wi", "url": "https://www.stocktitan.net/sec-filings/CUE/form-4-cue-biopharma-inc-insider-trading-activity-57378fc7ce2e.html", "source_name": "Stock Titan", "published_at": "2026-07-10T23:10:03", "published_display": "10 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma (CUE) CEO Shao-Lee Lin awarded 327,537-share RSU and PSU package", "summary": "Cue Biopharma's CEO, Shao-Lee Lin, was granted equity awards totaling 327,537 shares of common stock on July 9, 2026, comprising restricted stock units (RSUs) and performance stock units (PSUs). The RSUs will vest over 48 months, while the PSUs are tied to specific stock price ta", "url": "https://www.stocktitan.net/sec-filings/CUE/form-4-cue-biopharma-inc-insider-trading-activity-caa54d270c12.html", "source_name": "Stock Titan", "published_at": "2026-07-10T23:09:17", "published_display": "10 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma (CUE) director Sarraf Pasha receives 21,800 RSU equity award", "summary": "Cue Biopharma director Sarraf Pasha was granted 21,800 restricted stock units (RSUs), which will vest in three equal installments on July 9, 2027, 2028, and 2029, dependent on his continued service. Following this award and after a 1-for-30 reverse stock split on April 22, 2026, ", "url": "https://www.stocktitan.net/sec-filings/CUE/form-4-cue-biopharma-inc-insider-trading-activity-d5fb7f1e7f6e.html", "source_name": "Stock Titan", "published_at": "2026-07-10T23:09:17", "published_display": "10 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma (CUE) awards 21,800 restricted stock units to board director", "summary": "Cue Biopharma, Inc. (CUE) awarded 21,800 restricted stock units (RSUs) to board director Daniel A. Camardo. These RSUs will vest in three equal installments on July 9, 2027, July 9, 2028, and July 9, 2029, contingent on his continued service to the company. Following this transac", "url": "https://www.stocktitan.net/sec-filings/CUE/form-4-cue-biopharma-inc-insider-trading-activity-89b6fd53a7c5.html", "source_name": "Stock Titan", "published_at": "2026-07-10T23:09:17", "published_display": "10 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma Raises ~$50 Million in Private Placement With Cormorant, Columbia Threadneedle", "summary": "Cue Biopharma announced a private placement aiming to raise approximately $50 million. The financing, expected to close on July 13, 2026, involves investors like Cormorant Asset Management and Columbia Threadneedle Investments purchasing common shares and pre-funded warrants. The", "url": "https://www.tradingview.com/news/tradingview:4c99ce58f7742:0-cue-biopharma-raises-50-million-in-private-placement-with-cormorant-columbia-threadneedle/", "source_name": "TradingView", "published_at": "2026-07-10T21:09:17", "published_display": "10 Jul 2026 21:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue: The Market Is Paying $86M For A Drug It Doesn't Own (NASDAQ:CUE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPS3Nleng5OHFMOWZSa3M4RjQwNm5RSnYwd2NSendlektpQmV3ekUwUUdDdi11TVdsQzdPckNHZUtPX3dFdnAxeXFuX2dzOG5ReWE2X3k5WmJqd21QSTJfTTNJcmtPNVhHSTNMbFJvWTlDZnJFZ1R2YkZJdjFmQi1RWFhMcDRETzFFSE1YUVB1TDAyd1IxWkxSQmtn?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-10T19:05:30+00:00", "published_display": "10 Jul 2026 19:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma Shares Rise on $50 Million Private Placement Pricing", "summary": "Cue Biopharma announced the pricing of a $50 million private placement of its common stock and pre-funded warrants. The offering included existing as well as new investors. Proceeds from the placement are intended to fund the company's CUE-100 series clinical trials, expand the C", "url": "https://www.moomoo.com/news/post/72789621/cue-biopharma-shares-rise-on-50-million-private-placement-pricing", "source_name": "Moomoo", "published_at": "2026-07-10T17:10:03", "published_display": "10 Jul 2026 17:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma Announces $50 Million Private Placement", "summary": "Cue Biopharma has announced a private placement of its common stock and pre-funded warrants, aiming to raise approximately $50 million. The financing includes participation from existing investors, new healthcare-focused funds, and members of the company's management and board. P", "url": "https://www.moomoo.com/news/post/72764024/cue-biopharma-announces-50-million-private-placement", "source_name": "Moomoo", "published_at": "2026-07-10T09:09:17", "published_display": "10 Jul 2026 09:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma (CUE) Secures $50M in Private Placement Financing", "summary": "Cue Biopharma (CUE) has finalized a securities purchase agreement to raise approximately $50.0 million through an oversubscribed private placement with institutional investors. The company will issue 1.42 million shares at $33.21 each and pre-funded warrants. This funding aims to", "url": "https://www.gurufocus.com/news/8953157/cue-biopharma-cue-secures-50m-in-private-placement-financing", "source_name": "GuruFocus", "published_at": "2026-07-10T08:40:39", "published_display": "10 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma raises $50M in private placement", "summary": "Cue Biopharma (NASDAQ:CUE) announced a private placement to raise approximately $50 million by issuing common stock and pre-funded warrants to accredited investors. Cormorant Asset Management led the placement, with funds intended for clinical development and general corporate pu", "url": "https://m.uk.investing.com/news/stock-market-news/cue-biopharma-raises-50m-in-private-placement-93CH-4764988?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-10T03:40:39", "published_display": "10 Jul 2026 03:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech firm Cue Biopharma lines up $50M to push its immune disorder drugs", "summary": "Cue Biopharma announced a $50 million private placement, including common shares and pre-funded warrants, led by Cormorant Asset Management and Columbia Threadneedle Investments. The company plans to use the proceeds to fund clinical development and corporate purposes, specifical", "url": "https://www.stocktitan.net/news/CUE/cue-biopharma-announces-50-0-million-private-uhpijo1q77w2.html", "source_name": "Stock Titan", "published_at": "2026-07-10T02:40:39", "published_display": "10 Jul 2026 02:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma Announces $50 Million Private Placement Led by Cormorant Asset Management", "summary": "Cue Biopharma has secured $50 million through a private placement of common stock and pre-funded warrants, led by Cormorant Asset Management and including Columbia Threadneedle Investments. The funds will support clinical development and general corporate purposes, with the trans", "url": "https://www.quiverquant.com/news/Cue+Biopharma+Announces+%2450+Million+Private+Placement+Led+by+Cormorant+Asset+Management", "source_name": "Quiver Quantitative", "published_at": "2026-07-10T01:50:00", "published_display": "10 Jul 2026 01:50", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma Announces $50.0 Million Private Placement", "summary": "Cue Biopharma, Inc. announced a private placement of common stock and pre-funded warrants valued at approximately $50.0 million. The placement was led by Cormorant Asset Management and includes Columbia Threadneedle Investments with the proceeds intended for clinical development ", "url": "https://www.globenewswire.com/news-release/2026/07/10/3325290/0/en/cue-biopharma-announces-50-0-million-private-placement.html", "source_name": "GlobeNewswire", "published_at": "2026-07-09T21:40:00", "published_display": "09 Jul 2026 21:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma Company Profile & Introduction", "summary": "", "url": "https://news.google.com/rss/articles/CBMigwNBVV95cUxQWXNhb0ZTemRmd1M1cDBscF8tRUZPanNPVVlrc1Z0VTh5ZTlSUzBnSC1Bcm5GczlTQTJOZUNHT0ItcE9pRlRFU0o2ci0zNkVUNURaSTcyZGd1MXRSZEdVUV8wTnFFNEk3MkZDWnoxMFR6aVBOd1pfQ29fV2dyc081RUlKU3Q5cXI5d1RGTGM0TTRkYkZhNXB6WkJnejVLS0NBUVZPaDNwUHJoenFGdXFKeU44cGpPcUVHbUdaR25XdXYzR091TmR5YlFjQTE3cWpCT0JfX3A0blBNTDFXWS1RdklocXlOTzJmWGRPRExmRnBGQlRidHhEQXRvc3lLVDJtUXVrVjJrSnNaYzBvVTIySnFkWFZaUWlzUFpha1pSTlJCVHZNWWsxRkJMVm9pQzV5VnVQZ0NRaVdaRDU2djE2VjZtWDczTFNvYXdVbnhLZVVaRXFYSENmZXJSUGVVY2tGLVR5LWxoQUEwNjR0MWRSSmRQS0gtamVFYXl1SmdsNVFRQm8?oc=5", "source_name": "Moomoo", "published_at": "2026-07-08T17:26:26+00:00", "published_display": "08 Jul 2026 17:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma Inc outlines its immunotherapy approach for long-term investors", "summary": "Cue Biopharma Inc is a biotechnology company focused on developing targeted biologic therapies to modulate the human immune system for cancer and autoimmune diseases. Its business model centers on creating engineered biologic molecules that selectively engage disease-specific T c", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/cue-biopharma-inc-outlines-its-immunotherapy-approach-for-long-term/69715615", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T15:39:58", "published_display": "07 Jul 2026 15:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma, Inc. SEC Filing", "summary": "This article announces an EFFECT filing by Cue Biopharma, Inc. (CUE) with the SEC, indicating the effectiveness of its S-3 registration statement. The effectiveness date is July 1, 2026, at 4:00 P.M. The filing is deemed neutral in both impact and sentiment by Rhea-AI.", "url": "https://www.stocktitan.net/sec-filings/CUE/effect-cue-biopharma-inc-sec-filing-9787dbfc5b69.html", "source_name": "Stock Titan", "published_at": "2026-07-02T10:09:57", "published_display": "02 Jul 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Cue Biopharma, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQLVdFcHl0bDk1czFEV3V2Qnk2SWVYZTJ0WmNNeHZiYWMxZVJFNnZHOXBPZ09jRnd5eHNNQUJackpmR04wX2d4V08yQVBEV0VsdWFFY3BMZjlPTUwtcDJEYjVldUFKUUNaeFRVa1J6d3dzWHRKRkdwRzl0RWFTeGpYejVzcl9Rd1F2MDVsQ1E0XzNmVjE5cUlRbTM3c0Y?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Cue Biopharma, Inc. \u2013 LS:A426PN", "summary": "This page provides financial information for Cue Biopharma, Inc. (A426PN) traded on the Lang & Schwarz Tradecenter, specifically focusing on its \"Price to book forward\" metric. The article indicates that market data is provided by ICE Data Services, reference data by FactSet, and", "url": "https://www.tradingview.com/symbols/LS-A426PN/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T09:39:57", "published_display": "27 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Cue Biopharma, Inc. \u2013 NASDAQ:CUE", "summary": "This page provides financial data, specifically the price to book forward ratio, for Cue Biopharma, Inc. (NASDAQ: CUE). It also lists various tools and services offered by TradingView, including market data, charting libraries, and community features. The article indicates that t", "url": "https://www.tradingview.com/symbols/NASDAQ-CUE/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T22:11:20", "published_display": "26 Jun 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Cue Biopharma, Inc. \u2013 LS:A426PN", "summary": "This article focuses on the enterprise value to revenue forward a financial metric for Cue Biopharma, Inc. (A426PN). It indicates that the information is provided by TradingView, sourcing data from ICE Data Services, FactSet, American Bankers Association, and Quartr for SEC filin", "url": "https://www.tradingview.com/symbols/LS-A426PN/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T22:10:44", "published_display": "26 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Cue Biopharma, Inc. \u2013 LS:A426PN", "summary": "This article provides the enterprise value to EBITDA forward for Cue Biopharma, Inc. under the ticker LS:A426PN. The data is presented within a financial market context, likely TradingView, where users can find financial information, news, and community discussions. It serves as ", "url": "https://www.tradingview.com/symbols/LS-A426PN/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T10:39:55", "published_display": "26 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Cue Biopharma, Inc. \u2013 LS:A426PN", "summary": "This article provides financial information for Cue Biopharma, Inc. (LS:A426PN), specifically focusing on its forward price-to-earnings ratio. The content appears on TradingView, listing key financial metrics and indicating that the market for this stock is closed with no recent ", "url": "https://www.tradingview.com/symbols/LS-A426PN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T21:11:42", "published_display": "25 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma Files for Shares Sale by Shareholder", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/cue-biopharma-files-shares-sale-214116927.html", "source_name": "MT Newswires", "published_at": "2026-06-18T21:41:16+00:00", "published_display": "18 Jun 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cue-biopharma-announces-board-transition-200500807.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T20:05:00+00:00", "published_display": "02 Jun 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Cue Biopharma directors bring $1B-a-year drug launch experience", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQOUVvV0cxWTg3VV9KSS11UkJEVjRpakxlcGZQQmNTVzVueGRZb2JBUjg3UlhXV0dOQlVkYUtvLXROWWNuX0Z1YkxuTGUxTnNfQzZVTXBwSko5NWVyZUtpWW42dGJ3Q2FUc1BOTW1nSnBRWGJ5aFdhUGFfcVlZcmI1SzNJNWtGUEVaS1FlN0EtVk9lVWtoUUk1MDFvalV0OG5iV3RJRmttbnhyX2RiWk9ESEVCeEY?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma (NASDAQ: CUE) reshapes board, adds new legal and accounting leaders", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOcDNuTTZvbEJldTNHbk1zaXJsRmFSWEFHQ2RnSXZmQkVLMzEzLXlYNWZkYkRKbmpXcGNLNTJPSnFpM1FRNmw3aG5uVVZXdG5YUm1qZVVQS3RFYjlWaHJkT3hrajBWUzZ1UW1xOGdVMU5ORzVJZDdvT2RMTHZ1bzRTTzdzQmQtRG5zRl9XdzBzd0lfUlIzUk1sLTVZWFkyQnhMQXY3T0x2OHo?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cue-biopharma-present-2026-jefferies-200500229.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T20:05:00+00:00", "published_display": "21 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cue-biopharma-reports-first-quarter-200700010.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T20:07:00+00:00", "published_display": "14 May 2026 20:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cue-biopharma-reports-inducement-grants-230700816.html", "source_name": "GlobeNewswire", "published_at": "2026-05-07T23:07:00+00:00", "published_display": "07 May 2026 23:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma, Inc. Common Stock (CUE) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE5oOTVoN1pESzY3b1BkUEI2VjYyWkxsbXFPV0RvbkxOc2ZGSFFGcGZJUzB1dFJTMFhqdDF2ZUdXTzNGLXVFSkV1bndib2lIX1dlYUVSaHB3?oc=5", "source_name": "Gotrade", "published_at": "2026-05-07T20:51:31+00:00", "published_display": "07 May 2026 20:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma Announces $30 Million Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQSERzT0dybUNyaFdSRmpkb3ltOVZkajBLQ24yZndfdE9ka09nWG13NUZQSTItUXJ1Yml1TmNFQ3RjU0hMb0k2a3M3ZVBXMjdnS0pMUXdkVHdKME5IMHotdFQtNWxWbDZUNld3VGF2NUZETW5mdU85b245NnZQcENoek9UVUlXVjJJWm9ock9CcHZDSEV1ZDZjU193RnFxeTRqRzZxT3Z4Tmh2Uzl2V2pPc2lBWlFrdXF5U3pJTmNPZXFrdw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma lines up $30M to fund pipeline and Ascendant-221", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQSHZqSWpkYTFvVEF0X3ZrMlNtdW9YbkE5bjQ4b1ZpMno5ZG92U21CakFjemRKYmpBVmFRLW02MzJ6Njh2ejNWaHUzdXVtVFRPWU83YTdjajVsanBkRHhfLURqMjRWckdBZlJZeGRGRkZ0YV9IQTNTbjNfLUN4aHFBeGpqMG41U01peGwtcTNVN2ptNlBLNEJaczVVZWw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma secures $30M private placement financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQeUFDcV9hMmZKTGcycVU4bGpSNFdrU0VnZTdXWFUxeTdqOWtBaEVyUDlLQkstbmdyQThibGtXNVNrYmlFRFRxREJtTkRWVjR6N2plSDhpOGd3T0RTS1RSZ0RkYjR5Wm02eDlieENrdk5mbEVIUDBaZ2VjRFhCaWtMcUtHWXpZblQ0Sm1xTWZPQkZOOHFEc0VvNGl5SFBEZTZkWGtiWS1yT095U0Q5ek4w?oc=5", "source_name": "Investing.com", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cue Biopharma (NASDAQ: CUE) sets 1-for-30 reverse split to support Nasdaq bid", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQUXJ5TERVT0JVUGJqRjNuOFZTc0hzRE4ySkxrenlWREowZmVKZmhBM0ltZUVKRU1WOFg2N2dIaFZmZDhxMFRqUURERFZTTlJhLThNQ2Y5NmJnWmZWY29pMHBmUE5aNUdORFIwTElFUnVfX1pBdEgwVFhqdGo3VkphMDc1RVM0RHY0OEx3WlZLUmJUaG82cUZxSzdraFQxaGI0bjhXUEVGT1Q?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma Announces 1-for-30 Reverse Stock Split", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPWWo2eDNPSXE1dzNOT240UWx4RDVuemktWGRySVV4ZmNNSkZPRDNnU25JSEVyQS1jT1IyajVwSUVwQ0d2NDltbVpsQzZNTGg3dVhBa1UwcmdZaUllTmNIVi1NMi1uMHpreEVhRDU0ZWZoRVVZSmFQbXYxZ25fZDV0VXhTaUJ2M3hfM1J1dUEtbzFLY2cyN2VaOA?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Cue Biopharma (NASDAQ: CUE) to vote on 1-for-30\u20131-for-50 reverse split", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNMVFpN0laQVpjaHptUmFKU3ZQUnZYWFZPbG95bVg0UWVUM19US0cyMXZQdVVSQnc3ZmlpZDZjTU1pZ1pQWHZHMTNvUTJtWGhoX2NDd0R0RWNYR2pfMzhmUElqRDFsUENlYkxlRXJoaUF0cktBUmpHSFB5VkFiMV9laS1ndWgyWkY4M1h6OE55cnhXbkdNNExZNVVYYWh5Tm5Lam1HdWRxWHdfamxySEJ5OGpjUFk?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-06T08:00:00+00:00", "published_display": "06 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma, Inc. Announces Underwritten Public Offering of Common Stock and Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQZ0FKUEdJZzVIdkpCWlpXS2x6S2VHVWJYdVpRYjhtSWM3TTlEaXoxblRHenZFRF9CRzVBSEcwb0RRS1VvRnIxeUFlSGI4N0FFN3V6dW9LN0lkUkFUY25Rem05TUZEWF9oc2NNang4SG95aTQtWEg5TFlrUkdPc0dGekIxQ0FSQmtxZ2JnSG9YbEhjemhnS2Zzc3kyV0lWOEZ3UnlBZmUxV0dYUkpQSnYzWGZvdDVNeW1JaXhaT1g2aw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-12-18T08:00:00+00:00", "published_display": "18 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Form 4 Cue Biopharma For: 15 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPVHlMRmEwdXc3bWVGR1AtMFYzT3AyT2E0TzB1Ml9Ld254TUxFaDdxMWJwanB0WWc5V2FMUm5SNi01WG1pRnotVUs1djRZTDh6RV9hZTlwX0pDSWdvMDRkNnZCZDZkWTlGLWZRT19WQlN0YXphdW14aFhuaGF2djd3Vjg2UVlPb0xSTXpXLWRCYUdIMmpISWRiMA?oc=5", "source_name": "Investing.com Canada", "published_at": "2026-07-15T23:05:10+00:00", "published_display": "15 Jul 2026 23:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma (CUE) awards RSUs and stock options to CMO Borie", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQcEFTNWNjWURQY1Izck5uWVFmaVBjSWltWnR1b1J3eFdnNW1fLTJXbXR4cHhWYjl4bXoxbmhkenJwMXBXaGZNbHhSb1VlaVM4YXBxNWlmYkZ1WlJid2huTnpaMkRPeGNVR29GWExGZ3JfcVBOaE9RckNnQkVfWGFxWGlVajlNYWtmMm9tSENUMVFhTzA2NERHS002LW5VNjdKYXlBbkdlMzN5ckxtT1d3?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T23:00:15+00:00", "published_display": "15 Jul 2026 23:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma (NASDAQ: CUE) CMO Dominique Borie files initial Form 3", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQbEJ5aUN6Nm16cWxEQnRCSnFVQThTMVRJVjEtX2RCOTlKSHVFdVZkbGRHbktHX29GeG16bC00d0tfR0N4SXQ3U0ctaURjUThZRlJMM2ZJQm5ZME8zSV9ZRHBIZXBsT1ZTSGhnVGJnZ2llU2JZdEliWEpicXdCUEx0VXhSTWMxeEhsNFZOcmtpNno0YWVrRGo5SGlIYWhsLU84T3F1Wk9hSVlJM0E2WW9MSXlERGhiekJsVGN2V1NyR0d4cE9taFE?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-15T22:58:49+00:00", "published_display": "15 Jul 2026 22:58", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development", "summary": "Cue Biopharma (Nasdaq: CUE) has appointed Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development. Dr. Borie brings over two decades of experience in immunology and clinical development to the company and will report to President and CEO Shao-Lee L", "url": "https://www.globenewswire.com/news-release/2026/07/13/3326185/0/en/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-officer-and-head-of-research-development.html", "source_name": "GlobeNewswire", "published_at": "2026-07-13T15:40:13", "published_display": "13 Jul 2026 15:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma names Dominic Borie as chief medical officer", "summary": "Cue Biopharma has appointed Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development. This strategic move coincides with the company's advancement of therapies for immune-mediated diseases, including upcoming Phase 2 data for CUE-221 and the initiat", "url": "https://www.investing.com/news/company-news/cue-biopharma-names-dominic-borie-as-chief-medical-officer-93CH-4788521", "source_name": "Investing.com", "published_at": "2026-07-13T13:09:56", "published_display": "13 Jul 2026 13:09", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ETFs Investing in Cue Biopharma, Inc. Stocks", "summary": "This article lists Exchange Traded Funds (ETFs) that hold stocks of Cue Biopharma, Inc. (CUE). It highlights one such fund, the iShares Microcap ETF (IWC), providing details like its market value, weight of CUE stock, expense ratio, and performance. The information aims to help i", "url": "https://www.tradingview.com/symbols/NASDAQ-CUE/etfs/?exchange=NASDAQ", "source_name": "TradingView", "published_at": "2026-07-13T13:09:55", "published_display": "13 Jul 2026 13:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immunology veteran Dominic Borie to steer Cue Biopharma\u2019s drug pipeline", "summary": "Cue Biopharma (Nasdaq: CUE) has appointed Dominic Borie, M.D., Ph.D., as its Chief Medical Officer and Head of Research & Development. This strategic hire aligns with the company's advancement of its clinical programs, including an expected Phase 2 CSU data readout for CUE-221 by", "url": "https://www.stocktitan.net/news/CUE/cue-biopharma-appoints-dominic-borie-m-d-ph-d-as-chief-medical-0b47z37jap4b.html", "source_name": "Stock Titan", "published_at": "2026-07-13T12:09:55", "published_display": "13 Jul 2026 12:09", "sentiment": "positive", "sentiment_pct": 77, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech Stocks At 52-Week Highs: AMWL, CUE, ICCC, SRRK, FTH", "summary": "Several biotech stocks, including American Well Corporation (AMWL), Cue Biopharma Inc. (CUE), ImmuCell Corporation (ICCC), Scholar Rock Holding Corp. (SRRK), and Faeth Therapeutics Inc. (FTH), reached 52-week highs on July 10, 2026. These highs were driven by positive development", "url": "https://www.rttnews.com/amp/3666350/biotech-stocks-at-52-week-highs-amwl-cue-iccc-srrk-fth.aspx", "source_name": "RTTNews", "published_at": "2026-07-13T11:09:56", "published_display": "13 Jul 2026 11:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Cue Biopharma, Inc. \u2013 MUN:1UC0", "summary": "This article provides access to financial data for Cue Biopharma, Inc. (1UC0) on the Munich Stock Exchange, specifically focusing on its forward price-to-earnings ratio. It seems to be a financial data page from TradingView, offering an overview of the company's financial perform", "url": "https://www.tradingview.com/symbols/MUN-1UC0/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T19:40:43", "published_display": "12 Jul 2026 19:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Cue Biopharma, Inc. \u2013 MUN:1UC0", "summary": "This article displays the \"Enterprise value to revenue forward\" metric for Cue Biopharma, Inc. (MUN:1UC0) on the Munich Stock Exchange, as provided by TradingView. It shows that the market is currently closed with no trades recorded for this particular metric. The content highlig", "url": "https://www.tradingview.com/symbols/MUN-1UC0/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-07-12T08:39:50", "published_display": "12 Jul 2026 08:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma (CUE) director receives 21,800-share restricted stock unit grant", "summary": "Meehan Viola Mong, a director at Cue Biopharma, received a grant of 21,800 restricted stock units (RSUs) of Common Stock. These RSUs were granted at $0.00 per share and will vest in three equal installments on July 9, 2027, July 9, 2028, and July 9, 2029, contingent on continued ", "url": "https://www.stocktitan.net/sec-filings/CUE/form-4-cue-biopharma-inc-insider-trading-activity-32dc7de8f257.html", "source_name": "Stock Titan", "published_at": "2026-07-11T15:40:13", "published_display": "11 Jul 2026 15:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma (Nasdaq: CUE) secures $50M private placement and grants over 1M RSUs", "summary": "Cue Biopharma (Nasdaq: CUE) has successfully completed a private placement, raising approximately $50.0 million from accredited investors including Cormorant Asset Management and Columbia Threadneedle Investments. This financing involved issuing common stock and pre-funded warran", "url": "https://www.stocktitan.net/sec-filings/CUE/8-k-cue-biopharma-inc-reports-material-event-a63e850859e8.html", "source_name": "Stock Titan", "published_at": "2026-07-11T02:11:12", "published_display": "11 Jul 2026 02:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma (CUE) awards 21,800 time-vested RSUs to director Garzone", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxNSDgwb2JtMG83V2hkVDRGOS0zNjNTTjVaVVlIVXJJWEFHOHhlVWVfRFp3Uk9GN2FsekZjSDRnaXptam8waHJTX0hzbVcwOVF1Q2FsYW9LN0lNQ2owcmVETlYwX0FHT2ZOVS1uaDFvR0NrSkREVzFHMEFKUG1iWFVwTlJCYkV0bGVMLWd5dFdQajQxNEVfbUlGUHpNVlNEeDBReFBqVmoxMlNPWS1GZktj?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T23:38:30+00:00", "published_display": "10 Jul 2026 23:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 Cue Biopharma For: 10 July By Investing.com", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQRWZ5c25LTDZ5NFlvUXlBRGR1cGhMV0phQ0YzNTNKbC1meU5IMFZBbnV6aDQtMXp1dU5rUmxKSWwxczZMTFhRUXl3cHA0YmxUSGFvRnJaVFlqZndmQm4zMXJ2d2VyellSbTdmOHZWekpoYWxaZ3dIMWx5bTllX0IxakdKbEtxRm54M1lJcmYwXzlycnoyUzRBcg?oc=5", "source_name": "Investing.com UK", "published_at": "2026-07-10T23:38:00+00:00", "published_display": "10 Jul 2026 23:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma (CUE) awards 40,942 RSUs and 40,942 PSUs to accounting chief", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxOd3ZrSkJqM1BEZDB6NDFmYW9iOXV4YlBuVDdBZlZmNVdoWUN6bWNWUTBGRkJGdS10UkhEVEpuMFFYTDRKdjk5cVVOZTB4bWRrdGJMcDk2NHh0TWppMFR6UUFkanJzTkxnRVlBc2VNTGcxUlhsM2ZjOEpLZmtmZmdhcl8xQzMwNmJfcHl3N1VEbUFJOGV0RVlWNWFwUjM4cTBqNm9kMHdJSHFkWGUwUWlN?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-10T23:34:53+00:00", "published_display": "10 Jul 2026 23:34", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma (CUE) awards 109,178-share RSU and PSU package to legal chief", "summary": "Cue Biopharma, Inc. granted its Chief Legal Compliance Officer and Corporate Secretary, Sumita Ray, a total of 109,178 shares in equity awards. This package includes 54,589 restricted stock units (RSUs) vesting quarterly over 48 months and 54,589 performance stock units (PSUs) wi", "url": "https://www.stocktitan.net/sec-filings/CUE/form-4-cue-biopharma-inc-insider-trading-activity-57378fc7ce2e.html", "source_name": "Stock Titan", "published_at": "2026-07-10T23:10:03", "published_display": "10 Jul 2026 23:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma (CUE) CEO Shao-Lee Lin awarded 327,537-share RSU and PSU package", "summary": "Cue Biopharma's CEO, Shao-Lee Lin, was granted equity awards totaling 327,537 shares of common stock on July 9, 2026, comprising restricted stock units (RSUs) and performance stock units (PSUs). The RSUs will vest over 48 months, while the PSUs are tied to specific stock price ta", "url": "https://www.stocktitan.net/sec-filings/CUE/form-4-cue-biopharma-inc-insider-trading-activity-caa54d270c12.html", "source_name": "Stock Titan", "published_at": "2026-07-10T23:09:17", "published_display": "10 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma (CUE) director Sarraf Pasha receives 21,800 RSU equity award", "summary": "Cue Biopharma director Sarraf Pasha was granted 21,800 restricted stock units (RSUs), which will vest in three equal installments on July 9, 2027, 2028, and 2029, dependent on his continued service. Following this award and after a 1-for-30 reverse stock split on April 22, 2026, ", "url": "https://www.stocktitan.net/sec-filings/CUE/form-4-cue-biopharma-inc-insider-trading-activity-d5fb7f1e7f6e.html", "source_name": "Stock Titan", "published_at": "2026-07-10T23:09:17", "published_display": "10 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma (CUE) awards 21,800 restricted stock units to board director", "summary": "Cue Biopharma, Inc. (CUE) awarded 21,800 restricted stock units (RSUs) to board director Daniel A. Camardo. These RSUs will vest in three equal installments on July 9, 2027, July 9, 2028, and July 9, 2029, contingent on his continued service to the company. Following this transac", "url": "https://www.stocktitan.net/sec-filings/CUE/form-4-cue-biopharma-inc-insider-trading-activity-89b6fd53a7c5.html", "source_name": "Stock Titan", "published_at": "2026-07-10T23:09:17", "published_display": "10 Jul 2026 23:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma Raises ~$50 Million in Private Placement With Cormorant, Columbia Threadneedle", "summary": "Cue Biopharma announced a private placement aiming to raise approximately $50 million. The financing, expected to close on July 13, 2026, involves investors like Cormorant Asset Management and Columbia Threadneedle Investments purchasing common shares and pre-funded warrants. The", "url": "https://www.tradingview.com/news/tradingview:4c99ce58f7742:0-cue-biopharma-raises-50-million-in-private-placement-with-cormorant-columbia-threadneedle/", "source_name": "TradingView", "published_at": "2026-07-10T21:09:17", "published_display": "10 Jul 2026 21:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue: The Market Is Paying $86M For A Drug It Doesn't Own (NASDAQ:CUE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimgFBVV95cUxPS3Nleng5OHFMOWZSa3M4RjQwNm5RSnYwd2NSendlektpQmV3ekUwUUdDdi11TVdsQzdPckNHZUtPX3dFdnAxeXFuX2dzOG5ReWE2X3k5WmJqd21QSTJfTTNJcmtPNVhHSTNMbFJvWTlDZnJFZ1R2YkZJdjFmQi1RWFhMcDRETzFFSE1YUVB1TDAyd1IxWkxSQmtn?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-07-10T19:05:30+00:00", "published_display": "10 Jul 2026 19:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma Shares Rise on $50 Million Private Placement Pricing", "summary": "Cue Biopharma announced the pricing of a $50 million private placement of its common stock and pre-funded warrants. The offering included existing as well as new investors. Proceeds from the placement are intended to fund the company's CUE-100 series clinical trials, expand the C", "url": "https://www.moomoo.com/news/post/72789621/cue-biopharma-shares-rise-on-50-million-private-placement-pricing", "source_name": "Moomoo", "published_at": "2026-07-10T17:10:03", "published_display": "10 Jul 2026 17:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma Announces $50 Million Private Placement", "summary": "Cue Biopharma has announced a private placement of its common stock and pre-funded warrants, aiming to raise approximately $50 million. The financing includes participation from existing investors, new healthcare-focused funds, and members of the company's management and board. P", "url": "https://www.moomoo.com/news/post/72764024/cue-biopharma-announces-50-million-private-placement", "source_name": "Moomoo", "published_at": "2026-07-10T09:09:17", "published_display": "10 Jul 2026 09:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma (CUE) Secures $50M in Private Placement Financing", "summary": "Cue Biopharma (CUE) has finalized a securities purchase agreement to raise approximately $50.0 million through an oversubscribed private placement with institutional investors. The company will issue 1.42 million shares at $33.21 each and pre-funded warrants. This funding aims to", "url": "https://www.gurufocus.com/news/8953157/cue-biopharma-cue-secures-50m-in-private-placement-financing", "source_name": "GuruFocus", "published_at": "2026-07-10T08:40:39", "published_display": "10 Jul 2026 08:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma raises $50M in private placement", "summary": "Cue Biopharma (NASDAQ:CUE) announced a private placement to raise approximately $50 million by issuing common stock and pre-funded warrants to accredited investors. Cormorant Asset Management led the placement, with funds intended for clinical development and general corporate pu", "url": "https://m.uk.investing.com/news/stock-market-news/cue-biopharma-raises-50m-in-private-placement-93CH-4764988?ampMode=1", "source_name": "Investing.com", "published_at": "2026-07-10T03:40:39", "published_display": "10 Jul 2026 03:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biotech firm Cue Biopharma lines up $50M to push its immune disorder drugs", "summary": "Cue Biopharma announced a $50 million private placement, including common shares and pre-funded warrants, led by Cormorant Asset Management and Columbia Threadneedle Investments. The company plans to use the proceeds to fund clinical development and corporate purposes, specifical", "url": "https://www.stocktitan.net/news/CUE/cue-biopharma-announces-50-0-million-private-uhpijo1q77w2.html", "source_name": "Stock Titan", "published_at": "2026-07-10T02:40:39", "published_display": "10 Jul 2026 02:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma Announces $50 Million Private Placement Led by Cormorant Asset Management", "summary": "Cue Biopharma has secured $50 million through a private placement of common stock and pre-funded warrants, led by Cormorant Asset Management and including Columbia Threadneedle Investments. The funds will support clinical development and general corporate purposes, with the trans", "url": "https://www.quiverquant.com/news/Cue+Biopharma+Announces+%2450+Million+Private+Placement+Led+by+Cormorant+Asset+Management", "source_name": "Quiver Quantitative", "published_at": "2026-07-10T01:50:00", "published_display": "10 Jul 2026 01:50", "sentiment": "positive", "sentiment_pct": 67, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma Announces $50.0 Million Private Placement", "summary": "Cue Biopharma, Inc. announced a private placement of common stock and pre-funded warrants valued at approximately $50.0 million. The placement was led by Cormorant Asset Management and includes Columbia Threadneedle Investments with the proceeds intended for clinical development ", "url": "https://www.globenewswire.com/news-release/2026/07/10/3325290/0/en/cue-biopharma-announces-50-0-million-private-placement.html", "source_name": "GlobeNewswire", "published_at": "2026-07-09T21:40:00", "published_display": "09 Jul 2026 21:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma Company Profile & Introduction", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "Moomoo", "published_at": "2026-07-08T17:26:26+00:00", "published_display": "08 Jul 2026 17:26", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma Inc outlines its immunotherapy approach for long-term investors", "summary": "Cue Biopharma Inc is a biotechnology company focused on developing targeted biologic therapies to modulate the human immune system for cancer and autoimmune diseases. Its business model centers on creating engineered biologic molecules that selectively engage disease-specific T c", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/cue-biopharma-inc-outlines-its-immunotherapy-approach-for-long-term/69715615", "source_name": "AD HOC NEWS", "published_at": "2026-07-07T15:39:58", "published_display": "07 Jul 2026 15:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma, Inc. SEC Filing", "summary": "This article announces an EFFECT filing by Cue Biopharma, Inc. (CUE) with the SEC, indicating the effectiveness of its S-3 registration statement. The effectiveness date is July 1, 2026, at 4:00 P.M. The filing is deemed neutral in both impact and sentiment by Rhea-AI.", "url": "https://www.stocktitan.net/sec-filings/CUE/effect-cue-biopharma-inc-sec-filing-9787dbfc5b69.html", "source_name": "Stock Titan", "published_at": "2026-07-02T10:09:57", "published_display": "02 Jul 2026 10:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[EFFECT] Cue Biopharma, Inc. SEC Filing", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQLVdFcHl0bDk1czFEV3V2Qnk2SWVYZTJ0WmNNeHZiYWMxZVJFNnZHOXBPZ09jRnd5eHNNQUJackpmR04wX2d4V08yQVBEV0VsdWFFY3BMZjlPTUwtcDJEYjVldUFKUUNaeFRVa1J6d3dzWHRKRkdwRzl0RWFTeGpYejVzcl9Rd1F2MDVsQ1E0XzNmVjE5cUlRbTM3c0Y?oc=5", "source_name": "Stock Titan", "published_at": "2026-07-02T07:00:00+00:00", "published_display": "02 Jul 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Cue Biopharma, Inc. \u2013 LS:A426PN", "summary": "This page provides financial information for Cue Biopharma, Inc. (A426PN) traded on the Lang & Schwarz Tradecenter, specifically focusing on its \"Price to book forward\" metric. The article indicates that market data is provided by ICE Data Services, reference data by FactSet, and", "url": "https://www.tradingview.com/symbols/LS-A426PN/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-27T09:39:57", "published_display": "27 Jun 2026 09:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to book forward of Cue Biopharma, Inc. \u2013 NASDAQ:CUE", "summary": "This page provides financial data, specifically the price to book forward ratio, for Cue Biopharma, Inc. (NASDAQ: CUE). It also lists various tools and services offered by TradingView, including market data, charting libraries, and community features. The article indicates that t", "url": "https://www.tradingview.com/symbols/NASDAQ-CUE/financials-statistics-and-ratios/price-book-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T22:11:20", "published_display": "26 Jun 2026 22:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to revenue forward of Cue Biopharma, Inc. \u2013 LS:A426PN", "summary": "This article focuses on the enterprise value to revenue forward a financial metric for Cue Biopharma, Inc. (A426PN). It indicates that the information is provided by TradingView, sourcing data from ICE Data Services, FactSet, American Bankers Association, and Quartr for SEC filin", "url": "https://www.tradingview.com/symbols/LS-A426PN/financials-statistics-and-ratios/enterprise-value-sales-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T22:10:44", "published_display": "26 Jun 2026 22:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Enterprise value to EBITDA forward of Cue Biopharma, Inc. \u2013 LS:A426PN", "summary": "This article provides the enterprise value to EBITDA forward for Cue Biopharma, Inc. under the ticker LS:A426PN. The data is presented within a financial market context, likely TradingView, where users can find financial information, news, and community discussions. It serves as ", "url": "https://www.tradingview.com/symbols/LS-A426PN/financials-statistics-and-ratios/enterprise-value-ebitda-fwd/", "source_name": "TradingView", "published_at": "2026-06-26T10:39:55", "published_display": "26 Jun 2026 10:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Price to earnings forward of Cue Biopharma, Inc. \u2013 LS:A426PN", "summary": "This article provides financial information for Cue Biopharma, Inc. (LS:A426PN), specifically focusing on its forward price-to-earnings ratio. The content appears on TradingView, listing key financial metrics and indicating that the market for this stock is closed with no recent ", "url": "https://www.tradingview.com/symbols/LS-A426PN/financials-statistics-and-ratios/price-earnings-fwd/", "source_name": "TradingView", "published_at": "2026-06-25T21:11:42", "published_display": "25 Jun 2026 21:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma Files for Shares Sale by Shareholder", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/cue-biopharma-files-shares-sale-214116927.html", "source_name": "MT Newswires", "published_at": "2026-06-18T21:41:16+00:00", "published_display": "18 Jun 2026 21:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cue-biopharma-announces-board-transition-200500807.html", "source_name": "GlobeNewswire", "published_at": "2026-06-02T20:05:00+00:00", "published_display": "02 Jun 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "New Cue Biopharma directors bring $1B-a-year drug launch experience", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxQOUVvV0cxWTg3VV9KSS11UkJEVjRpakxlcGZQQmNTVzVueGRZb2JBUjg3UlhXV0dOQlVkYUtvLXROWWNuX0Z1YkxuTGUxTnNfQzZVTXBwSko5NWVyZUtpWW42dGJ3Q2FUc1BOTW1nSnBRWGJ5aFdhUGFfcVlZcmI1SzNJNWtGUEVaS1FlN0EtVk9lVWtoUUk1MDFvalV0OG5iV3RJRmttbnhyX2RiWk9ESEVCeEY?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma (NASDAQ: CUE) reshapes board, adds new legal and accounting leaders", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxOcDNuTTZvbEJldTNHbk1zaXJsRmFSWEFHQ2RnSXZmQkVLMzEzLXlYNWZkYkRKbmpXcGNLNTJPSnFpM1FRNmw3aG5uVVZXdG5YUm1qZVVQS3RFYjlWaHJkT3hrajBWUzZ1UW1xOGdVMU5ORzVJZDdvT2RMTHZ1bzRTTzdzQmQtRG5zRl9XdzBzd0lfUlIzUk1sLTVZWFkyQnhMQXY3T0x2OHo?oc=5", "source_name": "Stock Titan", "published_at": "2026-06-02T07:00:00+00:00", "published_display": "02 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cue-biopharma-present-2026-jefferies-200500229.html", "source_name": "GlobeNewswire", "published_at": "2026-05-21T20:05:00+00:00", "published_display": "21 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cue-biopharma-reports-first-quarter-200700010.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T20:07:00+00:00", "published_display": "14 May 2026 20:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/cue-biopharma-reports-inducement-grants-230700816.html", "source_name": "GlobeNewswire", "published_at": "2026-05-07T23:07:00+00:00", "published_display": "07 May 2026 23:07", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma, Inc. Common Stock (CUE) Stock Price Today & Analysis", "summary": "", "url": "https://news.google.com/rss/articles/CBMiVkFVX3lxTE5oOTVoN1pESzY3b1BkUEI2VjYyWkxsbXFPV0RvbkxOc2ZGSFFGcGZJUzB1dFJTMFhqdDF2ZUdXTzNGLXVFSkV1bndib2lIX1dlYUVSaHB3?oc=5", "source_name": "Gotrade", "published_at": "2026-05-07T20:51:31+00:00", "published_display": "07 May 2026 20:51", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma Announces $30 Million Private Placement", "summary": "", "url": "https://news.google.com/rss/articles/CBMiwgFBVV95cUxQSERzT0dybUNyaFdSRmpkb3ltOVZkajBLQ24yZndfdE9ka09nWG13NUZQSTItUXJ1Yml1TmNFQ3RjU0hMb0k2a3M3ZVBXMjdnS0pMUXdkVHdKME5IMHotdFQtNWxWbDZUNld3VGF2NUZETW5mdU85b245NnZQcENoek9UVUlXVjJJWm9ock9CcHZDSEV1ZDZjU193RnFxeTRqRzZxT3Z4Tmh2Uzl2V2pPc2lBWlFrdXF5U3pJTmNPZXFrdw?oc=5", "source_name": "GlobeNewswire", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma lines up $30M to fund pipeline and Ascendant-221", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxQSHZqSWpkYTFvVEF0X3ZrMlNtdW9YbkE5bjQ4b1ZpMno5ZG92U21CakFjemRKYmpBVmFRLW02MzJ6Njh2ejNWaHUzdXVtVFRPWU83YTdjajVsanBkRHhfLURqMjRWckdBZlJZeGRGRkZ0YV9IQTNTbjNfLUN4aHFBeGpqMG41U01peGwtcTNVN2ptNlBLNEJaczVVZWw?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma secures $30M private placement financing", "summary": "", "url": "https://news.google.com/rss/articles/CBMirwFBVV95cUxQeUFDcV9hMmZKTGcycVU4bGpSNFdrU0VnZTdXWFUxeTdqOWtBaEVyUDlLQkstbmdyQThibGtXNVNrYmlFRFRxREJtTkRWVjR6N2plSDhpOGd3T0RTS1RSZ0RkYjR5Wm02eDlieENrdk5mbEVIUDBaZ2VjRFhCaWtMcUtHWXpZblQ0Sm1xTWZPQkZOOHFEc0VvNGl5SFBEZTZkWGtiWS1yT095U0Q5ek4w?oc=5", "source_name": "Investing.com", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma (NASDAQ: CUE) sets 1-for-30 reverse split to support Nasdaq bid", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQUXJ5TERVT0JVUGJqRjNuOFZTc0hzRE4ySkxrenlWREowZmVKZmhBM0ltZUVKRU1WOFg2N2dIaFZmZDhxMFRqUURERFZTTlJhLThNQ2Y5NmJnWmZWY29pMHBmUE5aNUdORFIwTElFUnVfX1pBdEgwVFhqdGo3VkphMDc1RVM0RHY0OEx3WlZLUmJUaG82cUZxSzdraFQxaGI0bjhXUEVGT1Q?oc=5", "source_name": "Stock Titan", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma Announces 1-for-30 Reverse Stock Split", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxPWWo2eDNPSXE1dzNOT240UWx4RDVuemktWGRySVV4ZmNNSkZPRDNnU25JSEVyQS1jT1IyajVwSUVwQ0d2NDltbVpsQzZNTGg3dVhBa1UwcmdZaUllTmNIVi1NMi1uMHpreEVhRDU0ZWZoRVVZSmFQbXYxZ25fZDV0VXhTaUJ2M3hfM1J1dUEtbzFLY2cyN2VaOA?oc=5", "source_name": "Market source", "published_at": "2026-04-22T07:00:00+00:00", "published_display": "22 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma (NASDAQ: CUE) to vote on 1-for-30\u20131-for-50 reverse split", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNMVFpN0laQVpjaHptUmFKU3ZQUnZYWFZPbG95bVg0UWVUM19US0cyMXZQdVVSQnc3ZmlpZDZjTU1pZ1pQWHZHMTNvUTJtWGhoX2NDd0R0RWNYR2pfMzhmUElqRDFsUENlYkxlRXJoaUF0cktBUmpHSFB5VkFiMV9laS1ndWgyWkY4M1h6OE55cnhXbkdNNExZNVVYYWh5Tm5Lam1HdWRxWHdfamxySEJ5OGpjUFk?oc=5", "source_name": "Stock Titan", "published_at": "2026-03-06T08:00:00+00:00", "published_display": "06 Mar 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cue Biopharma, Inc. Announces Underwritten Public Offering of Common Stock and Warrants", "summary": "", "url": "https://news.google.com/rss/articles/CBMivwFBVV95cUxQZ0FKUEdJZzVIdkpCWlpXS2x6S2VHVWJYdVpRYjhtSWM3TTlEaXoxblRHenZFRF9CRzVBSEcwb0RRS1VvRnIxeUFlSGI4N0FFN3V6dW9LN0lkUkFUY25Rem05TUZEWF9oc2NNang4SG95aTQtWEg5TFlrUkdPc0dGekIxQ0FSQmtxZ2JnSG9YbEhjemhnS2Zzc3kyV0lWOEZ3UnlBZmUxV0dYUkpQSnYzWGZvdDVNeW1JaXhaT1g2aw?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-12-18T08:00:00+00:00", "published_display": "18 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 99, "total_relevant": 61, "sentiment_summary": {"positive": 14, "negative": 1, "neutral": 46, "score": 55, "total": 61, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 88, "events": [{"event": "general", "label": "Market update", "weight": 26.2, "count": 47}, {"event": "earnings", "label": "Earnings", "weight": 6.05, "count": 13}, {"event": "liquidity", "label": "Balance sheet", "weight": 0.55, "count": 1}], "positive_events": 14, "negative_events": 1}, "market_context": {"has_market_context": true, "latest_close": 36.78, "latest_week": "2026-07-10", "one_week_move": 30.1, "four_week_move": 49.9, "twelve_week_move": 102.2, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 0.676722, "market_dynamics_buy_signal": false, "relative_strength": 68.368578, "fair_value_gap": -4.5, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "negative", "expectation_probability": 39.4578, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+30.1% over one week, +49.9% over four weeks, trend active, and near fair-value range."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Stock Titan", "count": 19}, {"label": "TradingView", "count": 10}, {"label": "GlobeNewswire", "count": 7}, {"label": "Market source", "count": 6}, {"label": "Investing.com", "count": 3}, {"label": "Moomoo", "count": 3}, {"label": "Quiver Quantitative", "count": 2}, {"label": "simplywall.st", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 53}, {"label": "Industry context", "count": 8}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 47}, {"label": "Earnings", "count": 13}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "55/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "88/100 classification confidence."}, {"label": "Company focus", "value": "53", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+30.1% over one week, +49.9% over four weeks, trend active, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Form 4 Cue Biopharma For: 15 July By Investing.com"}], "updated_at": "2026-07-16T15:23:11.840207+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}